SCHEMBL4074953

SCHEMBL4074953

CCCc1nc2[nH]ncc2c(=O)n1Cc1ccccc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4A P27815 5/20 0.56
PDE4B Q07343 5/20 0.56
PDE4C Q08493 5/20 0.56
PDE4D Q08499 5/20 0.56
ADORA3 P0DMS8 4/20 0.54
ADORA2A P29274 3/20 0.47
MAPT P10636 2/20 0.47
KDM4E B2RXH2 1/20 0.46
CYP1A2 P05177 1/20 0.46
CYP2C9 P11712 1/20 0.46
CYP2C19 P33261 1/20 0.46
HSD17B10 Q99714 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
PDE3B Q13370 1/20 0.46
PDE3A Q14432 1/20 0.46
NPC1 O15118 1/20 0.45
GAA P10253 1/20 0.45
RAB9A P51151 1/20 0.45
PTGES O14684 3/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2348949 0.79 PDE4A (0.85) PDE4APDE4BPDE4CPDE4DMAPT
SCHEMBL6512906 0.78 PDE4A (0.86) PDE4APDE4BPDE4CPDE4DMAPT
SCHEMBL5563021 0.77 PDE4A (0.64) PDE4APDE4BPDE4CPDE4DMAPT
SCHEMBL6518180 0.76 PDE4A (0.66) PDE4APDE4BPDE4CPDE4DMAPT
SCHEMBL5353533 0.75 PDE4A (0.58) PDE4APDE4BPDE4CPDE4DMAPT
SCHEMBL4092061 0.75 PDE4A (0.61) PDE4APDE4BPDE4CPDE4DMAPT
SCHEMBL5103773 0.74 PDE4A (0.60) PDE4APDE4BPDE4CPDE4DMAPT
SCHEMBL6017115 0.74 PDE4A (0.56) PDE4APDE4BPDE4CPDE4DMAPT
SCHEMBL5765941 0.72 PDE4A (0.51) PDE4APDE4BPDE4CPDE4DMAPT
SCHEMBL14423584 0.72 PDE4A (0.57) PDE4APDE4BPDE4CPDE4DMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1458726-B1 MITOTIC KINESIN INHIBITORS MERCK & CO INC (US) 2009-07-15 EP disclosed
EP-1458726-B1 MITOTIC KINESIN INHIBITORS MERCK & CO INC (US) 2009-07-15 EP disclosed
US-7262186-B2 Substituted pyrazolo[3,4-d] pyrimidinones as a mitotic kinesin inhibitor MERCK & CO., INC. (US) 2007-08-28 US disclosed
US-7262186-B2 Substituted pyrazolo[3,4-d] pyrimidinones as a mitotic kinesin inhibitor MERCK & CO., INC. (US) 2007-08-28 US disclosed
US-7262186-B2 Substituted pyrazolo[3,4-d] pyrimidinones as a mitotic kinesin inhibitor MERCK & CO., INC. (US) 2007-08-28 US disclosed
EP-1458726-A4 MITOTIC KINESIN INHIBITORS MERCK & CO INC (US) 2006-01-25 EP disclosed
US-20050176737-A1 Mitotic kinesin inhibitors MERCK SHARP & DOHME CORP. 2005-08-11 US disclosed
EP-1458726-A2 MITOTIC KINESIN INHIBITORS Merck & Co., Inc. (US) 2004-09-22 EP disclosed
WO-2003049527-A2 MITOTIC KINESIN INHIBITORS MERCK & CO., INC. (US) 2003-06-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050176737-A1 Mitotic kinesin inhibitors KIF5B, KIFC1, KIF2C PDE4A 2777/4885PDE4B 3049/4885PDE4C 3086/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.